Skip to main content
Premium Trial:

Request an Annual Quote

Ag-Bio Startup Amfora Licenses CRISPR IP From Corteva, Broad Institute

NEW YORK (GenomeWeb) — Ag-bio startup Amfora announced today that it has acquired a nonexclusive license to intellectual property covering CRISPR-Cas9 genome editing and related technologies from DowDuPont's Corteva Agriscience and the Broad Institute.

San Francisco-based Amfora, which closed a $5 million Series A round roughly two years ago, aims to develop nutritionally enhanced food and feed crops. Under the terms of the license, Amfora will be able to use the IP to develop crops with increased protein content.

Additional terms were not disclosed.

"The CRISPR-Cas9 patent estate is a proven technology that we can use to develop our products," Amfora CSO Michael Lassner said in a statement. "Securing this license will allow us to effectively use our proprietary technology."

Earlier this year, Amfora said that it won a $350,000 grant from the United Soybean Board to develop soybean varieties with increased protein content.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.